Viridian Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Viridian Therapeutics's estimated annual revenue is currently $23.4M per year.
- Viridian Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Viridian Therapeutics has 151 Employees.
- Viridian Therapeutics grew their employee count by 30% last year.
Viridian Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Cofounder and Executive Advisor | Reveal Email/Phone |
2 | VP | Reveal Email/Phone |
3 | VP | Reveal Email/Phone |
4 | VP, Translational Medicine | Reveal Email/Phone |
5 | SVP Finance and Accounting | Reveal Email/Phone |
6 | SVP Regulatory Affairs and Quality Assurance | Reveal Email/Phone |
7 | SVP Technical Operations | Reveal Email/Phone |
8 | VP, CMC | Reveal Email/Phone |
9 | VP, Clinical Development | Reveal Email/Phone |
10 | VP, Project Leadership | Reveal Email/Phone |
Viridian Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.7M | 11 | 0% | N/A | N/A |
#2 | $2.8M | 18 | 13% | N/A | N/A |
#3 | $70.2M | 453 | -1% | N/A | N/A |
#4 | $1.6M | 10 | -66% | N/A | N/A |
#5 | $3.7M | 24 | -8% | N/A | N/A |
#6 | $2.9M | 37 | 28% | N/A | N/A |
#7 | $3.1M | 20 | 25% | N/A | N/A |
#8 | $2.5M | 16 | -20% | N/A | N/A |
#9 | $9.1M | 59 | 0% | N/A | N/A |
#10 | $4.2M | 27 | -7% | N/A | N/A |
What Is Viridian Therapeutics?
Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today's therapies. Viridian's most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal antibody in development for thyroid eye disease (TED). Viridian is headquartered in Boulder, Colo., with research and development operations in Waltham, Mass.
keywords:N/A
N/A
Total Funding
151
Number of Employees
$23.4M
Revenue (est)
30%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Viridian Therapeutics News
This table compares Sera Prognostics and Viridian Therapeutics' revenue, earnings per share and valuation. Gross Revenue, Price/Sales Ratio, Net...
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Recommendation of Buy by Analysts. Posted by admin on Apr 12th, 2022.
Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by...
Other Companies in Boulder
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $37.9M | 151 | 2% | N/A |
#2 | $38.4M | 153 | -1% | N/A |
#3 | $42.5M | 154 | 4% | N/A |
#4 | $25.5M | 160 | -20% | N/A |
#5 | $31.9M | 161 | 6% | N/A |